A First Semimanual Device for Clinical Intramuscular Repetitive Cell Injections

Intramuscular cell transplantation in humans requires so far meticulous repetitive cell injections. Performed percutaneously with syringes operated manually, the procedure is very time consuming and requires a lot of concentration to deliver the cells exactly in the required region. This becomes impractical and inaccurate for large volumes of muscle. In order to accelerate this task, to render it more precise, and to perform injections more reproducible in large volumes of muscle, we developed a specific semimanual device for intramuscular repetitive cell injections. Our prototype delivers very small quantities of cell suspension, homogeneously throughout several needles, from a container in the device. It was designed in order to deliver the cells as best as possible only in a given subcutaneous region (in our case, skeletal muscles accessible from the surface), avoiding wasting in skin and hypodermis. The device was tested in monkeys by performing intramuscular allotransplantations of β-galactosidase-labeled myoblasts. During transplantations, it was more ergonomic and considerably faster than manually operated syringes, facilitating the cell graft in whole limb muscles. Biopsies of the myoblast-injected muscles 1 month later showed abundant β-galactosidase-positive myofibers with homogeneous distribution through the biopsy sections. This is the first device specifically designed for the needs of intramuscular cell transplantation in a clinical context.

[1]  G. Butler-Browne,et al.  In vivo myogenic potential of human CD133+ muscle-derived stem cells: a quantitative study. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[2]  J. Micallef,et al.  Transplantation of adult myoblasts or adipose tissue precursor cells by high‐density injection failed to improve reinnervated skeletal muscles , 2008, Muscle & nerve.

[3]  J. Rousseau,et al.  Autologous transplantation of muscle precursor cells modified with a lentivirus for muscular dystrophy: human cells and primate models. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[4]  K. Mamchaoui,et al.  Premature proliferative arrest of cricopharyngeal myoblasts in oculo-pharyngeal muscular dystrophy: Therapeutic perspectives of autologous myoblast transplantation , 2006, Neuromuscular Disorders.

[5]  Giulio Cossu,et al.  Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs , 2006, Nature.

[6]  L. Casteilla,et al.  Transplantation of Adipose Tissue-Derived Stromal Cells Increases Mass and Functional Capacity of Damaged Skeletal Muscle , 2004, Cell transplantation.

[7]  D. Skuk,et al.  Cell therapies for inherited myopathies. , 2003, Current opinion in rheumatology.

[8]  N. Bresolin,et al.  Cell Therapy of α-Sarcoglycan Null Dystrophic Mice Through Intra-Arterial Delivery of Mesoangioblasts , 2003, Science.

[9]  J. Huard,et al.  Muscle-derived stem cells: characterization and potential for cell-mediated therapy. , 2001, Blood cells, molecules & diseases.

[10]  A. Miller,et al.  Systemic production of human granulocyte colony-stimulating factor in nonhuman primates by transplantation of genetically modified myoblasts. , 2000, Human gene therapy.

[11]  D. Skuk,et al.  Myoblast Transplantation in Whole Muscle of Nonhuman Primates , 2000, Journal of neuropathology and experimental neurology.

[12]  R. Roy,et al.  Very efficient myoblast allotransplantation in mice under FK506 immunosuppression , 1994, Muscle & nerve.

[13]  H. Blau,et al.  Systemic delivery of human growth hormone by injection of genetically engineered myoblasts. , 1991, Science.

[14]  A. Ossipov,et al.  Duchenne muscular dystrophy , 2004 .